Contents of volume 23

No. 1 (pp 1– 62) published November 28, 1988
No. 2 (pp 63–128) published December 14, 1988
No. 3 (pp 129–196) published February 14, 1989
No. 4 (pp 197–268) published March 20, 1989
No. 5 (pp 269–336) published April 3, 1989
No. 6 (pp 337–402) published April 12, 1989

This volume contains two supplements:

1. Abstracts of the 13th Congress of the European Society for Medical Oncology. October 30 – November 1, 1988, Lugano, Switzerland, pp C1–C 122
2. First International Symposium on Treatment of Liver Cancer, 15–16 November 1987, Kobe, Japan, pp S 1–S 132

Abe M → Hirai K
Acton EM → Cramer SC
Adam J → Russell J
Aihara H → Nakaike S
Akamatsu K, Miyauchi S, Ohshima K, Yasuhara Y, Mogami H, Ohta Y, Hamamoto K: Alleviation of gallbladdder complications by treatment of hepatic arterial embolization with caerulein S 59
Akaza H, Hagiwara M, Deguchi N, Kawai T, Satomi Y, Matsuda T, Miki T, Ueda T, Kotake T, Tazaki H, Aso Y, Niijima T, Carboplatin Study Group: Phase II trial of carboplatin in patients with advanced germ-cell testicular tumors and transitional cell carcinomas of the urinary tract 181
Al-Baker S → Khokhar AR
Ames MM → Frank SK
Anderson EG → Banks J
Andrews PM, Johnson CL Jr: Regional chemotherapy in an experimental model of Wilms' tumor in rats 31
Aoki Y → Hirai K
Arakawa K → Ichida T
Arbuck SG → Creaven PJ
Ardiet C → Tranchand B
Arii S → Tanaka J
Armand J-P → Bonnay MM
Aso Y → Akaza H
Autissier N → Dumas M
Avila LA → Peters RH

Baba H → Okamura T
Balazsovits JAE, Mayer LD, Bally MB, Cullis PR, McDonell M, Ginsberg RS, Falk RE: Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin 81
Bally MB → Balazsovits JAE
Banks J, Anderson EG, Smith AP: Failure of response to ifosfamide in squamous cell bronchogenic carcinoma 128
Bast RC Jr → Peters WP
Beckman EM → Colombo N
Beller U → Colombo N
Belpomme D → Martin P
Bence J → Pályi I
Benedict WF → White L
Benjamin RS → Raber MN
Biedler JL → Roberts D
Biron P → Tranchand B
Blackburn M → Choonara I
Blackledge G → Redman Ch
Blackledge GRP → Stuart NSA
Blum RH → Colombo N
Bonnay MM, Recondo G, Gouyette AJ, Armand J-P: A new anticancer agent (LY 186641) interferes with creatinine assay 119
Bons J → Marty M
Boossy J → Focan C
Borch RF → DeGregorio MW
Boré P, Rahmani R, Cantfort J van, Focan C, Cano JP: Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods 247
Bosanquet AG: Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. III Antimetabolites, tubulin-binding agents, platinum drugs, amsacrine, L-asparaginase, interferons, steroids and other miscellaneous antitumor agents 197
Boughton BJ → Donohue SM
Boxall FE → Newell DR
Brandon CS → Peters RH
Brasch H → Fahrig L
Brenner DE → Creaven PJ
Brion PN → Marty M
Brown DB → Khokhar AR
Brynjolf I → Havsteen H
Bugat R → Martin P
Bungo M → Sasaki Y
Bunni MA, Rembiesa BM, Priest DG, Sahovic E, Stuart R: Accumulation of tetrahydrofolates in human plasma after leucovorin administration 353
Buxton J → Redman Ch

Calvert AH → Graham MA
Calvert AH → Newell DR
Canetta R → Colombo N
Cano JP → Boré P
Cantfort J van → Boré P
Cantwell BMJ, Veale D, Rivett C, Ghani S, Harris AL: Cisplatin with high-dose infusions of hydroxyurea to inhibit DNA repair. A phase II study in non-small-cell-lung cancer 252
Carboplatin Study Group → Akaza H
Carlsson G, Gustavsson B, Hafström L: Effect on liver tumor growth in rats of allopurinol and 5-flurouracil in combination with hepatic artery ligation 169
Cassidy J, Kerr DJ, Setanoians A, Zaharko DS, Kaye SB: Could interspecies differences in the protein binding of flavone acetic acid contribute to the failure to predict lack of efficacy in patients? 397
Cavo M → Tura S
Chadoint-Noudeau V → Dumas M
Chamberlain M → Levin VA
Chan CSP, Schechter GP: In vitro evidence for dose-dependent cytotoxicity as the predominant effect of low dose Ara-C on human leukemic and normal marrow cells 87
Chang J-M → Yang C-F
Chan GTC → Liang R
Chang T-J → P'eng F-K
Chan TK → Liang R
Chan W-K → Lai K-H
Chazard M → Martin P
Chen C-L, Fang K-M, Hui Y-L: Eyperience with major hepatic resections for hepatocellular carcinoma S 101
Chen G-H → Yang C-F
Chetiyawardana A → Redman Ch
Chiang R-H → Yang C-F
Choonara I, Wheeldon J, Rayner P, Blackburn M, Lewis I: Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia 392
Claessens JJ → Focan C
Colombo N, Speyer JL, Green M, Canetta R, Beller U, Wernz JC, Meyers M, Widman T, Blum RH, Piccart M, Muggia FM, Beckman EM: Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients 323
Colvin OM → Peters RH
Cordel K → Vaughan WP
Cornbleet MA → Leonard RCF
Cornbleet MA, Kingsnorth A, Tell GP, Haegele KD, Joder-Ohlenbusch A-M: Phase I study of methylacetylenic putrescine, an inhibitor of polyamine biosynthesis 348
Coronado E → DeGregorio MW
Cowens JW → Creaven PJ
Cowens JW → Creaven PJ
Cramer SC, Rhodes RH, Acton EM, Tökés ZA: Neurotoxicity and dermatotoxicity of cyanomorpholinyl adriamycin 71
Crawford M → Redman Ch
Crawford SM → Stuart NSA
Creaven PJ → Petrelli NJ
Creaven PJ → Petrelli NJ
Creaven PJ, Brenner DE, Cowens JW, Huben RP, Wolf RM, Takita H, Arbuck SG, Razack MS, Proefrock AD: A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days 186
Creaven PJ, Cowens JW, Huben R, Petrelli N, Karakousis C, Traynor D: Phase I trial of a new nitrosourea, CGP 6809, given every 2 weeks 266
Cullis PR → Balazsovits JAE

Daoud SS, Juliano RL: In vitro effect of liposome-incorporated valinomycin on growth and macromolecular synthesis of normal and *ras*-transformed 3T3 cells 151
Dal Bo V → Veronesi A
Dardir M, Herman EH, Ferrans VJ: Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats 269
d'Athis P → Dumas M
DeGregorio MW, Coronado E, Osborne CK: Tumor and serum tamoxifen concentrations in the athymic nude mouse 68
DeGregorio MW, Wiebe VJ, Venook AP, Holleran WM: Elevated plasma tamoxifen levels in a patient with liver obstruction 194
DeGregorio MW, Gandara DR, Holleran WM, Perez EA, King CC, Wold HG, Montine TJ, Borch RF: High-dose cisplatin with diethyldithiocarbamate (DDTC) rescue therapy: preliminary pharmacologic observations 276
Deguchi N → Akaza H
de Jong PE → Willems PHB
Dekken H van → Nooter K
Delestrain MC → Martin P
Della Valentina M → Veronesi A
Denham A → Lawrence HJ
Dombernowsky P → Havsteen H
Donohue SM, Boughton BJ: Fractionated anthracycline therapy in acute myeloblastic leukaemia in adults 401
Droz JP → Marty M
Dulmadge EA → Wilkoff LJ
Dumas M, Gislain C de, d'Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, Autissier N: Evaluation of the effect of furosemide on ultrafilterable platinum kinetics in patients treated with *cis*-diamminedichloroplatinum 37
Durivage HJ → Hait WN

Eeles RA → Newell DR
Eguchi K → Sasaki Y
Eisenhauer E → O'Dwyer PJ
Elema JD → Willemse PHB
Ellman M → Gunnarsson PO
Engh G van den → Nooter K
Ensminger W: Hepatic arterial chemotherapy for primary and metastatic liver cancers S 68
Escousse A → Dumas M
Esumi M, Tanaka Y, Tozuka S, Shikata T: Clonal state of human hepatocellular carcinoma and non-tumorous hepatocytes S 1
Evans PC → Paxton JW

Fahrig L, Brasch H, Iven H: Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX 156
Falk RE → Balazsovits JAE
Fang K-M → Chen C-L
Ferrans VJ → Dardir M
Figlin RJ → Hait WN
Flebig H-H, Widmer KH, Winterhalter BR, Löhr GW: CGP 6809 – A new nitrosoureido-sugar derivative with activity in human tumor xenografts 337
Fletcher S → Leonard RCF
Focan C, Boossy J, Focan-Henrard D, Reginster M, Claessens JJ: Phase II trial with high-dose ifosfamide and mesna given in a 24-h infusion for advanced GI tract cancer 192
Focan C → Boré P
Focan-Henrard D → Focan C
Foglesong PD → Roberts D
Foot A → Moncrieff M
Forgeson G → Gore M
Foster BJ → Graham MA
Francini M → Veronesi A
Frank SK, Mathiesen DA, Szurszewski M, Kuffel MJ, Ames MM: Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174 piroxanthrone) 213
Fujii T → Sakura H
Fujimoto T → Hirai K
Fujisawa J → Kusamo M
Fujita M → Imaoka S
Fujiwara Y → Sasaki Y
Fukuda I → Imaoka S
Fukuda M → Sasaki Y
Furukawa H → Imaoka S

Galieni P → Tura S
Gandara DR → DeGregorio MW
Gandara DR → Lawrence HJ
Gera S, Musch E, Osterheld HKO, Loos U: Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma 76
Ghani S → Cantwell BMJ
Gherlinzoni F → Tura S
Gilbert C → Peters WP
Ginsberg RS → Balazsovits JAE
Gislain C de → Dumas M
Gockerman J → Peters WP
Godtfredsen J → Havsteen H
Goodnight SH → Lawrence HJ
Gore M, Powles R, Lakhani A, Milan S, Maitland J, Goss G, Nandi A, Perren T, Forgeson G, Treleaven J, Zulable A, Porta F: Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide 373
Gorski C → Raber MN
Goss G → Gore M
Gotoh M → Monden M
Gouyette AJ → Bonnay MM
Graham MA, Newell DR, Foster BJ, Calvert AH: The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients 8
Green M → Colombo N
Grem JL → O'Dwyer PJ
Grieve RJ → Sangster G
Griswold DP Jr → Wilkoff LJ
Guerrin J → Dumas M
Guidici D → Zaccheo T
Gumbrell LA → Newell DR
Gunnarsson PO, Vibe-Petersen J, Macpherson JS, Warrington PS, Polacek J, Ellman M, Hansen HH, Smyth JF: Pharmacokinetics of tauromustine in cancer patients. Phase I studies 176
Gustavsson B → Carlsson G

Habrand JL → Vassal G
Hacker MP → Khokhar AR
Hada Y → Hatano K
Haegele KD → Cornbleet MA
Hafström L → Carlsson G
Hagiwara M → Akaza H
Hait WN, Morris S, Lazo JS, Figlin RJ, Durivage HJ, White K, Schwartz PE: Phase I trial of combined therapy with bleomycin and the calmodulin antagonist, trifluoperazine 358
Hamamoto K → Akamatsu K
Hansen HH → Gunnarsson PO
Hardy JR → Paxton JW
Harper PG → Philip PA
Harris AL → Cantwell BMJ
Harris RI → Sangster G
Hartmann O → Vassal G
Hasegawa H → Shimamura Y
Hasegawa H → Takayasu K
Hashimoto N, Kawai S, Mikuriya S, Oda T, Inoue J, Shimamura Y, Takahashi A, Masuzawa M, Yumoto Y, Makino M, National Hospitals Multicenter Study Group for Liver Cancer Treatment: Effects of transcatheter arterial chemoembolization with oral chemotherapy on hepatic neoplasmas S 21
Hatano K, Mikuriya S, Oda T, Makino M, Hada Y: Hepatic irradiation in primary and metastatic liver cancer S 49
Havsteen H, Brynjolf I, Svahn T, Dombernowsky P, Godtfredsen J, Munck O: Prospective evaluation of chronic cardiotoxicity due to high-dose epirubicin or combination chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil 101
Hayashibara K → Hirosawa A
Hennik MB van, Vijgh WJF van der, Klein I, Vermorken JB, Pinedo HM: Human pharmacokinetics of carboplatin after oral administration 126
Heritier F → Martin P
Herman EH → Dardir M
Herrera L → Petrelli NJ
Herrera L → Petrelli NJ
Higano CS, Livingston RB: Oral dipyridamole and methotrexate in human solid tumors: a toxicity trial 259
Higuchi K → Ichida T
Hill BT, Hosking LK, Shellard SA, Whelan RDH: Comparative effectiveness of mitoxantrone and doxorubicin in overcoming experimentally induced drug resistance in murine and human tumour cell lines in vitro 140
Hirai K, Kawazoe Y, Yamashita K, Aoki Y, Fujimoto T, Sakai T, Majima Y, Abe M, Tanikawa K: Arterial chemotherapy and transcatheter arterial embolization therapy for non-resectable hepatocellular carcinoma S 37
Hirai S → Katagiri Y
Hiramatsu K → Ido K
Hirayama T: A large-scale cohort study on

risk factors for primary liver cancer, with special reference to the role of cigarette smoking S 114
Hirosawa A, Niitani H, Hayashibara K, Tsuboi E: Effects of sodium thiosulfate in combination therapy of *cis*-dichlorodiammineplatinum and vindesine 255
Hoffman R → Stuart NSA
Holleran WM → DeGregorio MW
Holleran WM → DeGregorio MW
Holm C → Vaughan WP
Horichi N → Sasaki Y
Horie T → Une Y
Horita S → Kusano M
Horwich A → Newell DR
Hosking LK → Hill BT
Hoth DF → O'Dwyer PJ
Ho Y-Z → Yang C-F
Huben R → Creaven PJ
Huben RP → Creaven PJ
Hui Y-L → Chen C-L
Hullan L → Pályi I

Ichida F → Ichida T
Ichida T, Higuchi K, Arakawa K, Ohta H, Sugiyama K, Miyagiwa M, Nohzawa A, Satoh T, Sasaki H, Ichida F: Treatment of hepatocellular carcinoma utilizing lymphokine-activated killer cells and interleukin-2 S 45
Ichihara T → Nakaike S
Ido K, Hiramatsu K: Effect of caerulein on abdominal pain following transcatheter hepatic arterial embolization in malignant liver cancer patients S 65
Ikeda N → Katagiri Y
Imaoka S, Sasaki Y, Shibata T, Fujita M, Kasugai H, Kojima J, Ishiguro S, Ohigashi H, Ishikawa O, Fukuda I, Furukawa H, Koyama H, Iwanaga T: A pre-operative chemoembolization therapy using lipiodol, cisplatin and gelatin sponge for hepatocellular carcinoma S 126
Inaba M → Ozawa S
Inazuki K → Nakaike S
Inoue J → Hashimoto N
Inoue S → Kawano N
Ishiguro S → Imaoka S
Ishii M → Shimamura Y
Ishikawa O → Imaoka S
Ishikawa Y → Kusano M
Itakura T → Katagiri Y
Itoh T → Sakata Y
Iven H → Fahrig L
Iwamoto K → Katagiri Y
Iwanaga T → Imaoka S

Jenkins RL, Pinson CW, Stone MD: Experience with transplantation in the treatment of liver cancer S 104
Joder-Ohlenbusch A-M → Cornbleet MA
Johnson CL Jr → Andrews PM
Jones RB → Peters WP
Jonker R → Nooter K
Juliano RL → Daoud SS

Kable EPW, Parsons PG: Melanin synthesis and the action of L-dopa and 3,4-dihydroxybenzylamine in human melanoma cells 1
Kakita A → Une Y
Kakizoe S → Kojiro M
Kanter PM → Schieweck K
Karakousis C → Creaven PJ
Kasugai H → Imaoka S
Katagiri Y, Mabuchi K, Itakura T, Naora K, Iwamoto K, Nozu Y, Hirai S, Ikeda N, Kawai T: Adriamycin-Lipiodol suspension for i.a. chemotherapy of hepatocellular carcinoma 238
Kawai S → Hashimoto N
Kawai T → Akaza H
Kawai T → Katagiri Y
Kawamura A → Kusano M
Kawano N, Ohmori Y, Inoue S, Nagao T, Morioka Y: Long-term prognosis of surgical patients with hepatocellular carcinoma S 129
Kawazoe Y → Hirai K
Kaye SB → Russell J
Kaye SB → Cassidy J
Kerr DJ → Cassidy J
Kerr GR → Leonard RCF
Khokhar AR, Brown DB, McCormack JJ, Hacker MP: Synthesis and antitumor activity of a series of (aminoethylpyrrolidine) platinum complexes 15
Khokhar AR, Al-Baker S, Krakoff IH, Perez-Soler R: Toxicity and antitumor activity of *cis*-bis-carboxylato (*trans*-R,R-1,2-diaminocyclohexane) platinum(II) complexes entrapped in liposomes 219
Kim BS → Yoo HS
Kim BS, Yoo HS, Park YJ, Loh JJK: Current status and future aspects on treatment of liver cancer S 118
Kim DI → Yoo HS
King CC → DeGregorio MW
King SA → O'Dwyer PJ
Kingsnorth A → Cornbleet MA
Kitai Y → Shimamura Y
Kitaya T → Shimamura Y
Kiyomatsu K → Kojiro M
Klein I → Hennik MB van
Klotman M → Peters WP
Kobayashi K → Monden M
Kojima J → Imaoka S
Kojiro M, Sugihara S, Kakizoe S, Nakashima O, Kiyomatsu K: Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy S 4
Komatsu Y → Sakata Y
Köpf-Maier P: Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract 225
Korenaga D → Okamura T
Kotake T → Akaza H
Koyama H → Imaoka S
Krakoff IH → Khokhar AR
Krakoff IH → Raber MN
Kuffel MJ → Frank SK
Kume S → Ozaki Y
Kuroda C → Monden M
Kuroda C → Sakurai M
Kusano M, Mito M, Nakanishi M, Matushima T, Une Y, Suga M, Sekiya C, Ishikawa Y, Horita S, Kawamura A, Sakamoto S, Fujisawa J, Uekita Y: Cooperative study on arterial regional chemotherapy for primary liver cancer in Hokkaido S 17

Lai K-H, Tsai Y-T, Lee S-D, Ng W-W, Teng H-C, Tam T-N, Lo G-H, Lin H-C, Lin H-J, Wu J-C, Lay C-S, Wang S-S, Chan W-K: Phase II study of mitoxantrone in unresectable primary hepatocellular carcinoma following hepatitis B infection 54
Lai K-H → Yang C-F
Lakhani A → Gore M
Laster WR Jr → Wilkoff LJ
Lawrence HJ, Walsh D, Zapotowski KA, Denham A, Goodnight SH, Gandara DR: Topical dimethylsulfoxide may prevent tissue damage from anthracycline extravasation 316
Lawton F → Redman Ch
Lay C-S → Lai K-H
Lazo JS → Hait WN
Lee JT → Yoo HS
Lee S-D → Lai K-H
Lee S-D → Yang C-F
Legha S → Raber MN
Lemerle J → Vassal G
Lemoli RM → Tura S
Leonard RCF, Smart GE, Livingstone JRB, Cornbleet MA, Kerr GR, Fletcher S, Webb JN, Smyth JF: Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma 105
Levin VA, Chamberlain M, Silver P, Rodriguez L, Prados M: Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia 301
Lewis I → Choonara I
Leyland MJ → Sangster G
Liang R, Chan TK, Chan GTC, Todd D: Treatment of adult acute lymphoblastic leukaemia using an intensive chemotherapy protocol 384
Lin H-C → Lai K-H
Lin H-J → Lai K-H
Liu T-J → Yang C-F
Livingstone JRB → Leonard RCF
Livingston RB → Higano CS
Lo G-H → Lai K-H
Loh JJK → Kim BS
Löhr GW → Flebig H-H
Lombardi P → Zaccheo T
Loos U → Gera S
Loos U → Oppitz MM
Lu K → Raber MN
Lui W-Y → P'eng F-K
Lui W-Y → Yang C-F

Mabuchi K → Katagiri Y
Macpherson JS → Gunnarsson PO
Madejewicz S → Petrelli NJ
Madsen MT → Yoo HS
Maitland J → Gore M
Majima Y → Hirai K
Makino M → Hashimoto N
Makino M → Hatano K
Malek M → Oppitz MM
Martin P, Bugat R, Pinon G, Pinel MC, Heritier F, Chazard M, Delestrain MC, Belpomme D: 300 mg/m² carboplatin

(Cb), Adriamycin (A) cyclophosphamide (C) (CaCb-300) combination in advanced ovarian carcinoma: a feasibility study 331
Marty M, Droz JP, Pouillart P, Paule B, Brion PN, Bons J: GR38032F, a5HT$_3$ receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting 389
Marukawa T → Sakurai M
Masuzawa M → Hashimoto N
Mathiesen DA → Frank SK
Matsuda T → Akaza H
Matsui T → Ohishi H
Matsuyama T → Shimamura Y
Matter A → Schieweck K
Matushima T → Kusano M
Mayer LD → Balazsovits JAE
Mazza P → Tura S
McCormack JJ → Khokhar AR
McDonell M → Balazsovits JAE
Merlo A → Veronesi A
Meyers M → Colombo N
Meyers MB → Roberts D
Midorikawa H → Yodono H
Migita Y → Nakaike S
Miki T → Akaza H
Mikuriya S → Hashimoto N
Mikuriya S → Hatano K
Milan S → Gore M
Minato K → Sasaki Y
Minematsu S → Tanaka J
Minuit M-P → Tranchand B
Mito M → Kusano M
Mittelman A → Petrelli NJ
Mittelman A → Petrelli NJ
Miura T: Treatment of hepatic cancer by hepatic arterial infusion chemotherapy S 121
Miyagiwa M → Ichida T
Miyauchi S → Akamatsu K
Mogami H → Akamatsu K
Moncrieff M, Foot A: Fanconi syndrome after ifosfamide 121
Monden M, Okamura J, Sakon M, Gotoh M, Kobayashi K, Umeshita K, Yamada T, Kuroda C, Sakurai M, Mori T: Significance of transcatheter chemoembolization combined with surgical resection for hepatocellular carcinomas S 90
Monden M → Sakurai M
Monfardini S → Veronesi A
Montine TJ → DeGregorio MW
Moore JO → Peters WP
Morino T → Tanaka J
Morioka Y → Kawano N
Mori T → Monden M
Moriyama N → Takayasu K
Morris S → Hait WN
Mould J → Redman Ch
Muggia FM → Colombo N
Mühlenbruch B → Oppitz MM
Mulder NH → Willemse PHB
Müller M → Schieweck K
Munck O → Havsteen H
Muramatsu Y → Takayasu K
Musch E → Gera S
Musch E → Oppitz MM

Nagao T → Kawano N
Nagasue N, Yukaya H: Liver resection for hepatocellular carcinoma: results from 150 consecutive patients S 78
Nakagawa K → Sasaki Y
Nakaike S, Yamagishi T, Samata K, Nishida K, Inazuki K, Ichihara T, Migita Y, Otomo S, Aihara H, Tsukagoshi S: In vivo activity on murine tumors of a novel antitumor compound, *N*-β-dimethylaminoethyl-9-carboxy-5-hydroxy-10-methoxybenzo[a]-phenazine-6-carboxamide sodium salt (NC-190) 135
Nakanishi M → Kusano M
Nakashima O → Kojiro M
Nandi A → Gore M
Naora K → Katagiri Y
National Hospitals Multicenter Study Group for Liver Cancer Treatment → Hashimoto N
Nazarbaghi R → Webber S
Newell DR → Graham MA
Newell DR, Eeles RA, Gumbrell LA, Boxall FE, Horwich A, Calvert AH: Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma 367
Newlands ES → Stuart NSA
Newman RA → Raber MN
Ng W-W → Lai K-H
Niijima T → Akaza H
Niimi S → Sasaki Y
Niitani H → Hirosawa A
Nishida K → Nakaike S
Nohzawa A → Ichida T
Nooter K, Oostrum R, Jonker R, Dekken H van, Stokdijk W, Engh G van den: Effect of cyclosporin A on daunorubicin accumulation in multidrug-resistant P388 leukemia cells measured by real-time flow cytometry 296
Nozu Y → Katagiri Y

O'Brien M → Redman Ch
Oda T → Hashimoto N
Oda T → Hatano K
O'Dwyer PJ, King SA, Eisenhauer E, Grem JL, Hoth DF: Hypersensitivity reactions to deoxycoformycin 173
Ogasawara K → Une Y
Ohashi T → Sakura H
Ohe Y → Sasaki Y
Ohigashi H → Imaoka S
Ohishi H, Yoshimura H, Uchida H, Sakaguchi H, Yoshioka T, Ohue S, Matsui T, Takaya A, Tsujii T: Transcatheter arterial embolization using iodized oil (lipiodol) mixed with an anticancer drug for the treatment of hepatocellular carcinoma S 33
Ohmori Y → Kawano N
Ohshima K → Akamatsu K
Ohta H → Ichida T
Ohta Y → Akamatsu K
Ohue S → Ohishi H
Okamoto E → Yamanaka N
Okamura J → Monden M
Okamura J → Sakurai M
Okamura T, Korenaga D, Baba H, Saito A, Sugimachi K: Postoperative adjuvant chemotherapy inhibits early recurrence of early gastric carcinoma 319
Okazaki N → Takayasu K
Okita S → Akamatsu K
Oon C-J, Rauff A, Tan LKA: Treatment of primary liver cancer in Singapore. A review of 3200 cases seen between January 1, 1977, and July 31, 1987 S 13
Oostrum R → Nooter K
Oppitz MM, Musch E, Malek M, Rüb HP, Unruh GE von, Loos U, Mühlenbruch B: Studies on the pharmacokinetics of chlorambucil and prednimustine in patients using a new high-performance liquid chromatographic assay 208
Osaka Study Group on Hepatocellular Carcinoma: Studies on the chemotherapy with 5-fluorouracil in transcatheter arterial chemoembolization (TAE) treated patients with resectable or non-resectable hepatocellular carcinoma S 29
Osborne CK → DeGregorio MW
Osterheld HKO → Gera S
Otomo S → Nakaike S
Oyama T → Ozaki Y
Ozaki Y, Oyama T, Kume S: Exacerbation of toxic effects by endotoxin contamination of recombinant human tumor necrosis factor 231
Ozawa S, Inaba M: Kinetic analysis of the in vitro cell-killing activity of neocarzinostatin 279

Pályi I, Bence J, Szikla K, Hullan L: Dominance of resistance to the alkylating agent 1,2:5,6-dianhydrogalactitol in P388 mouse lymphoma hybrid cells 41
Parganas E → Roberts D
Park CH → Yoo HS
Park YJ → Kim BS
Parsons PG → Kable EPW
Patterson M → Redman Ch
Patton WN → Sangster G
Paule B → Marty M
Paxton JW, Evans PC, Hardy JR: The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of *N*-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenyl-amino]-4-acridinecarboxamide (CI-921) in the rabbit 291
P'eng F-K, Wu C-W, Chang T-J, Lui W-Y: A comparison of regional versus systemic drug injection. Adriamycin concentration in peripheral blood and gastric stump (post-Billroth II gastrectomy) in the dog 363
Perez EA → DeGregorio MW
Perez-Soler R → Khokhar AR
Perren T → Gore M
Peters RH, Brandon CS, Avila LA, Colvin OM, Stuart RK: In vitro synergism of 4-hydroperoxy-cyclophosphamide and cisplatin: relevance for bone marrow purging 129
Peters WP, Stuart A, Klotman M, Gilbert C, Jones RB, Shpall EJ, Gockerman J, Bast RC Jr, Moore JO: High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study 377
Petrelli N → Creaven PJ

Petrelli NJ, Madejewicz S, Rustum Y, Herrera L, Creaven PJ, Plager J, Soloman J, Mittelman A: Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma 57
Petrelli NJ, Creaven PJ, Herrera L, Mittelman A: Phase II trial of continuous-infusion iproplatin (CHIP) and 5-fluorouracil (5-FU) in advanced colorectal carcinoma 61
Philip PA, Harper PG, Rogers HJ: Effect of cancer chemotherapy on dapsone N-acetylation in man 395
Philip T → Tranchand B
Piccart M → Colombo N
Pico JL → Vassal G
Pinedo HM → Hennik MB van
Pinel MC → Martin P
Pinon G → Martin P
Pinson CW → Jenkins RL
Plager J → Petrelli NJ
Ploin Y-D → Tranchand B
Polacek J → Gunnarsson PO
Poletti G → Tura S
Porta F → Gore M
Pouillart P → Marty M
Powles R → Gore M
Prados M → Levin VA
Priest DG → Bunni MA
Proefrock AD → Creaven PJ

Raber MN, Newman RA, Lu K, Legha S, Gorski C, Benjamin RS, Krakoff IH: Phase I clinical trial and pharmacokinetic evaluation of 4′-0-tetrahydropyranyladriamycin (THP-adriamycin) 311
Rahmani R → Boré P
Rauff A → Oon C-J
Rayner P → Choonara I
Razack MS → Creaven PJ
Re GL → Veronesi A
Recondo G → Bonnay MM
Redman Ch, Lawton F, Stuart N, O'Brien M, Buxton J, Mould J, Chetiyawardana A, Crawford M, Patterson M, Sykes V, Blackledge G: Phase II study of combination 4′-epidoxorubicin and mitomycin C in recurrent epithelial ovarian cancer 51
Reginster M → Focan C
Rembiesa BM → Bunni MA
Rhodes RH → Cramer SC
Rivett C → Cantwell BMJ
Roberts D, Meyers MB, Biedler JL, Wiggins LG: Association of sorcin with drug resistance in L1210 cells 19
Roberts D, Foglesong PD, Parganas E, Wiggins L: Reduced formation of lesions in the DNA of a multidrug-resistant L1210 subline selected for teniposide resistance 161
Rodriguez L → Levin VA
Rogers HJ → Philip PA
Rüb HP → Oppitz MM
Russell J, Adam J, Wheldon TE, Kaye SB: The relative effectiveness of analogues of cisplatin in the experimental chemotherapy of human non-small-cell lung cancer and neuroblastoma grown as multicellular spheroids 111
Rustum Y → Petrelli NJ

Sahovic E → Bunni MA
Saijo N → Sasaki Y
Saikawa Y → Yodono H
Saito A → Okamura T
Saitoh S → Sakata Y
Saito Y → Yodono H
Sakaguchi H → Ohishi H
Sakai T → Hirai K
Sakamoto S → Kusano M
Sakata Y, Komatsu Y, Takagi S, Saitoh S, Itoh T, Suzuki H, Tsushima K, Sasaki D, Yoshida Y: Randomized controlled study of mitomycin C/carboquone/5-fluorouracil/OK-432 (MQ-F-OK) therapy and mitomycin C/5-fluorouracil/doxorubicin (FAM) therapy against advanced liver cancer S 9
Sakon M → Monden M
Sakura H, Fujii T, Ohashi T, Tsuruta: Occurrence of an anti-peplomycin IgE antibody crossreacting with bleomycin in a patient with cervical uterine cancer 333
Sakurai M → Monden M
Sakurai M, Wakasa K, Monden M, Yamada T, Kuroda C, Marukawa T, Okamura J: Hepatocellular carcinoma in adenomatous hyperplasia of the liver S 110
Salle E di → Zaccheo T
Samata K → Nakaike S
Sangster G, Patton WN, Harris RI, Grieve RJ, Leyland MJ: Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide 263
Sano F → Une Y
Sapet C → Tranchand B
Sasaki D → Sakata Y
Sasaki H → Ichida T
Sasaki Y, Tamura T, Eguchi K, Shinkai T, Fujiwara Y, Fukuda M, Ohe Y, Bungo M, Horichi N, Niimi S, Minato K, Nakagawa K, Saijo N: Pharmacokinetics of (glycolato-0,0′)-diammine platinum (II), a new platinum derivative, in comparison with cisplatin and carboplatin 243
Sasaki Y → Imaoka S
Satoh T → Ichida T
Satomi Y → Akaza H
Sato Y → Une Y
Schechter GP → Chan CSP
Schieweck K, Stanek J, Kanter PM, Schmidt-Ruppin KH, Müller M, Matter A: CGP 6809, a sugar-containing nitrosourea derivative: pharmacological and physicochemical properties 341
Schmidt-Ruppin KH → Schieweck K
Schwartz PE → Hait WN
Sekiya C → Kusano M
Setanoians A → Cassidy J
Shellard SA → Hill BT
Shibata T → Imaoka S
Shikata T → Esumi M
Shimamura Y → Hashimoto N
Shimamura Y, Takenaka Y, Ishii M, Shima Y, Taniguchi H, Kitai Y, Watanabe H, Sugai S, Takashi A, Kitaya T, Matsuyama T, Hasegawa H: Multimodal treatment of hepatocellular carcinoma S 87
Shima Y → Shimamura Y
Shinkai T → Sasaki Y
Shpall EJ → Peters WP
Silver P → Levin VA
Slack J → Stuart NSA
Smart GE → Leonard RCF
Smith AP → Banks J
Smyth JF → Leonard RCF
Smyth JF → Gunnarsson PO
Soloman J → Petrelli NJ
Speyer JL → Colombo N
Stanek J → Schieweck K
Stevens MFG → Stuart NSA
Stokdijk W → Nooter K
Stone MD → Jenkins RL
Stuart A → Peters WP
Stuart N → Redman Ch
Stuart NSA, Crawford SM, Blackledge GRP, Newlands ES, Slack J, Hoffman R, Stevens MFG: A phase I study of meta-azidopyrimethamine ethanesulphonate (MZPES) – a new dihydrofolate reductase inhibitor 308
Stuart R → Bunni MA
Stuart RK → Peters RH
Sugai S → Shimamura Y
Suga M → Kusano M
Sugihara S → Kojiro M
Sugimachi K → Okamura T
Sugiyama K → Ichida T
Suh JH → Yoo HS
Suzuki H → Sakata Y
Suzuki M → Takayasu K
Svahn T → Havsteen H
Sykes V → Redman Ch
Szikla K → Pályi I
Szirth BC → White L
Szurszewski M → Frank SK

Takagi S → Sakata Y
Takahashi A → Hashimoto N
Takashi A → Shimamura Y
Takaya A → Ohishi H
Takayasu K, Suzuki M, Uesaka K, Muramatsu Y, Moriyama N, Yoshida T, Yoshino M, Okazaki N, Hasegawa H: Hepatic artery embolization for inoperable hepatocellular carcinoma; prognosis and risk factors S 123
Takekawa S → Yodono H
Takenaka Y → Shimamura Y
Takita H → Creaven PJ
Talamini R → Veronesi A
Tam T-N → Lai K-H
Tamura T → Sasaki Y
Tanaka J, Tobe T, Morino T, Arii S, Minematsu S: Clinicopathological features of malignancy in hepatocellular carcinoma S 96
Tanaka Y → Esumi M
Taniguchi H → Shimamura Y
Tanikawa K → Hirai K
Tan LKA → Oon C-J
Tassi C → Tura S
Tazaki H → Akaza H
Tell GP → Cornbleet MA

Teng H-C → Lai K-H
Tirelli U → Veronesi A
Tobe T → Tanaka J
Todd D → Liang R
Tökés ZA → Cramer SC
Tozuka S → Esumi M
Tranchand B, Ploin Y-D, Minuit M-P, Sapet C, Biron P, Philip T, Ardiet C: High-dose melphalan dosage adjustment: possibility of using a test-dose 95
Traynor D → Creaven PJ
Treleaven J → Gore M
Tsai Y-T → Lai K-H
Tsai Y-T → Yang C-F
Tsujii T → Ohishi H
Tsukagoshi S → Nakaike S
Tsuruta → Sakura H
Tsushima K → Sakata Y
Tura S, Mazza P, Gherlinzoni F, Zinzani PL, Poletti G, Visani G, Lemoli RM, Cavo M, Galieni P, Tassi C, Zanchini R: Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodkin's lymphomas 123
Tusboi E → Hirosawa A

Uchida H → Ohishi H
Uchino J → Une Y
Ueda T → Akaza H
Uekita Y → Kusano M
Uesaka K → Takayasu K
Umeshita K → Monden M
Une Y → Kusano M
Une Y, Uchino J, Horie T, Sato Y, Ogasawara K, Kakita A, Sano F: Liver resection using a water jet S 74
Unruh GE von → Oppitz MM

Vassal G, Hartmann O, Habrand JL, Pico JL, Lemerle J: Enhanced cutaneous radiation effects following high-dose busulfan therapy 117
Vaughan WP, Holm C, Cordel K: Hydroxyurea potentiation of the antineoplastic activity of cyclophosphamide and 4'-(9-acridinylamino)methanesulfon-M-anisidide (AMSA) in the brown Norway rat myelocytic leukemia model 26
Veale D → Cantwell BMJ
Venook AP → DeGregorio MW
Vermorken JB → Hennik MB van
Veronesi A, Dal Bo V, Re GL, Della Valentina M, Tirelli U, Merlo A, Talamini R, Francini M, Monfardini S: Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study 115
Vibe-Petersen J → Gunnarsson PO
Vijgh WJF van der → Hennik MB van
Visani G → Tura S

Wakasa K → Sakurai M
Walsh D → Lawrence HJ
Wang S-S → Lai K-H
Warrington PS → Gunnarsson PO
Watanabe H → Shimamura Y
Webber S, Nazarbaghi R: The transport of pteridines in CCRF-CEM human lymphoblastic cells 283
Webb JN → Leonard RCF
Wernz JC → Colombo N
Wheeldon J → Choonara I
Whelan RDH → Hill BT
Wheldon TE → Russell J
White K → Hait WN
White L, Szirth BC, Benedict WF: Evaluation of response to chemotherapy in retinoblastoma heterotransplanted to the eyes of nude mice 63
Widman T → Colombo N
Widmer KH → Flebig H-H
Wiebe VJ → DeGregorio MW
Wiggins L → Roberts D
Wiggins LG → Roberts D
Wilkoff LJ, Dulmadge EA, Laster WR Jr, Griswold DP Jr: Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-β-*D*-arabinofuranosylcytosine 145
Willemse PHB, Jong PE de, Elema JD, Mulder NH: Severe renal failure following high-dose ifosfamide and mesna 329
Winterhalter BR → Flebig H-H
Wold HG → DeGregorio MW
Wolf RM → Creaven PJ
Wu C-W → P'eng F-K
Wu J-C → Lai K-H

Yamada T → Monden M
Yamada T → Sakurai M
Yamagishi T → Nakaike S
Yamanaka N, Okamoto E: Conditions favoring long-term survival after hepatectomy for hepatocellular carcinomas S 83
Yamashita K → Hirai K
Yang C-F, Ho Y-Z, Chang J-M, Chiang R-H, Lai K-H, Lee S-D, Tsai Y-T, Lui W-Y, Liu T-J, Chen G-H: Transcatheter arterial chemoembolization for hepatocellular carcinoma S 26
Yasuhara Y → Akamatsu K
Yodono H, Saito Y, Saikawa Y, Midorikawa H, Yokoyama Y, Takekawa S: Combination chemoembolization therapy for hepatocellular carcinoma: mainly, using cisplatin (CDDP) S 42
Yokoyama Y → Yodono H
Yoo HS, Park CH, Suh JH, Lee JT, Kim DI, Kim BS, Madsen MT: Radioiodinated fatty acid esters in the management of hepatocellular carcinoma: preliminary findings S 54
Yoo HS → Kim BS
Yoshida T → Takayasu K
Yoshida Y → Sakata Y
Yoshimura H → Ohishi H
Yoshino M → Takayasu K
Yoshioka T → Ohishi H
Yukaya H → Nagasue N
Yumoto Y → Hashimoto N

Zaccheo T, Giudici D, Lombardi P, Salle E di: A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors 47
Zaharko DS → Cassidy J
Zanchini R → Tura S
Zapotowski KA → Lawrence HJ
Zinzani PL → Tura S
Zulable A → Gore M